Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 318 participants.

Also called NCT05503953

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 318 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05503953
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05503953. Randomized; double masking; primary purpose treatment. Start 2022-09-13 (actual); primary completion 2025-06-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
Condition
Essential Hypertension
Intervention (Drug)
AGSAVI
Intervention (Drug)
AGLS
Lead sponsor
Ahn-Gook Pharmaceuticals Co.,Ltd (class: industry)
Collaborator
Daehwa Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05503953
Content hash
64f62c803a129b889a29e157d93b6c4ff3b1fbcebf9b40e74839bbda0c085733